Enzolytics Inc (ENZC)

[Mutat]

I believe this is it.


January 25, 2017
MONROVIA, CA / ACCESSWIRE / January 25, 2017 / Immunotech Laboratories, Inc. (OTC PINK: IMMB – Greymarket) (the"Company" or "IMMB") announced today the completion of successful clinical Phase III testing on patients suffering from HIV/AIDS of its patented medical product, ITV-1-ImmunH treatment. The clinical trials were conducted through IMMB's subsidiary, Immunotech Laboratories BG – Europe ("IMMB-BG") at the Specialized Hospital for Active Treatment of Infectious and Parasite Diseases – "Prof. Ivan Kirov", Sofia Bulgaria. The trials, using the most current state of the art clinical testing methods available, which were approved at the World Practice Show, revealed significant positive results in treating the deadly disease. Data from the final report shows improvement in immune indices in the absolute number of LY, CD3 T, CD4 T, CD8 T, B Ly, NK levels and in the percentage of CD3 T, CD4 T, CD8 T, B Ly, NK and in the CD4/CD8 index. Most importantly, viral loads in approximately 80% of the blood samples of the patients, after completion of the treatment cycles, came back at non-detectable levels. Other important results noted in the summary report were the positive treatment effect on opportunistic infections, compatibility with all other antiviral drugs, high level of tolerance in all patients and the complete lack of any negative side effects.